EVMN Evommune, Inc.
Evommune, Inc. (EVMN) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.82 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +6.9% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Evommune, Inc.
Evommune Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. Evommune Inc. is based in PALO ALTO, Calif.
Sector
Healthcare
Industry
Biotechnology